Chai Discovery, the AI company building a computer-aided design suite for protein-based therapeutics, today announced a collaboration with Roche to use Chai’s AI models and platform in a number of drug discovery programs across its therapeutic areas. “We are delighted to see Chai's models being used by Roche in their portfolio,” said Joshua Meier, co-founder and CEO of Chai Discovery. “This expands the range of therapeutic programs that can benefit from AI-driven molecular design.” "Chai’s pla

First clinical trial combining a Vβ-directed selective T-cell agonist with an ADC supports invikafusp alfa’s potential as a precision immune amplifier and IO backbone for broader cancer patient populations Encouraging clinical activity observed across two different metastatic breast cancer populations including HR-positive/HER2-negative metastatic breast cancer, where most patients derive limited benefit from checkpoint inhibition, and metastatic TNBC Maturing results demonstrate reductions in t

Mentari is advancing a robust pipeline of biologics for the prevention of migraine, including MT-001 and MT-002, which target clinically validated pathways and have potential to address the two-thirds of people who have a suboptimal response to existing anti-CGRP therapies Phase 1 clinical trial for MT-001, a monoclonal antibody targeting PACAP, ongoing with initial data expected mid-2027 MT-002, a bispecific antibody targeting both PACAP and CGRP, is on track for regulatory filing in Q1 2027 wi

Nov. 08, 2026 -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in registrational Phase III study of the Company's novel BCL2 inhibitor mesutoclax (ICP-248) in combination with azacitidine versus venetoclax with azacitidine in elderly or unfit patients with treatment naive (TN) acute myeloid leukemia (AML). Mesutoclax is a novel, oral BCL2 inhibitor

Data presented at AASLD The Liver Meeting demonstrated 100% of participants (28/28) who completed Week 96 of combination therapy reached undetectable virus (as defined by HDV RNA TND) Separate, exploratory analysis suggests curative potential with 10/10 patients who discontinued treatment after at least 96 weeks of undetectable virus showing sustained viral response (SVR) after 12 to 48 weeks of follow-up Conference call to discuss topline ECLIPSE 1 results and expanded SOLSTICE data scheduled f

In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in the Ntrust-2 study of NKX019, an investigational, allogeneic CAR NK cell therapy. In systemic sclerosis, 6/7 (86%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved a revised Composite Response Index in Systemic Sclerosis (rCRISS)-25 response or greater, wit

FDA assigns a PDUFA target action date of April 9, 2027 Combination achieved a median overall survival of 23.8 months in patients with unresectable or metastatic HCC, compared to sorafenib’s mOS of 15.2 months Nov. 05, 2026 -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients with cancer, today announced the U.S. Food and Drug Administration (FDA) acknowl

ArrayPatch Completes Oversubscribed €3.2 Million Seed Financing to Advance Next-Generation Microneedle Therapeutics Nov. 05, 2026 -- ArrayPatch Ltd (“ArrayPatch”), a biotech company developing innovative microneedle-based therapeutics, today announced the successful completion of the second close of its seed financing round, securing an additional €1.6 million, bringing the total raised to €3.2 million. The latest investment comes from impact-focused venture capital firm WakeUp Capital along w

November 5, 2026 - Zenith Epigenetics Ltd. ("Zenith" or the "Company") today announced that the Company has executed a Clinical Trial Collaboration and Supply Agreement ("CTCSA") with Eli Lilly & Company ("Lilly") for the upcoming registration enabling study of ZEN-3694, the Company's clinical oncology candidate, and Lilly's CDK4/6 inhibitor, Verzenio (abemaciclib), for the treatment of NUT carcinoma. Under the terms of the agreement, Zenith will sponsor and conduct the study, and Lilly will sup

Jyseleca® (filgotinib) has received expanded approval for the treatment of patients with active axial spondylarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have not responded adequately to conventional therapy. EC approval follows a positive opinion from the CHMP in September 2026 and offers a new treatment option for people living with inadequately controlled axSpA in Europe. An application has been submitted to the MHRA for UK approval and is under review.